**Table 2**. Patients and tumor characteristics of the UPS subgroup overall and according to treatment group.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | Overall | Preoperative chemotherapy  | Preoperative radiotherapy  | Concurrent chemo-radiotherapy  |   |
|   | N = 167 | N = 38 | N = 60 | N = 69 | SMD |
|   | n (%) | n (%) | n (%) | n (%) |   |
| Sex |   |   |   |   | 0,054 |
| Male | 97 (58.1) | 23 (60.5) | 35 (58.3) | 39 (56.5) |   |
| Female | 70 (41.9) | 15 (39.5) | 25 (41.7) | 30 (43.5) |   |
| Age |   |   |   |   | 0,822 |
| Median (1st and 3rd quartile) | 63.03 (54.63; 71.03) | 58.67 (50.40; 63.16) | 70.95 (63.53; 76.77) | 61.70 (50.39; 66.49) |   |
| Tumor site |   |   |   |   | 0,253 |
| Upper limb | 25 (15.0) | 5 (13.2) | 11 (18.3) | 9 (13.0) |   |
| Trunk wall | 29 (17.4) | 5 (13.2) | 15 (25.0) | 9 (13.0) |   |
| Lower limb | 113 (67.7) | 28 (73.7) | 34 (56.7) | 51 (73.9) |   |
| Depth |   |   |   |   | 0,181 |
| Superficial | 6 (3.6) | 1 (2.6) | 4 (6.7) | 1 (1.4) |   |
| Deep | 161 (96.4) | 37 (97.4) | 56 (93.3) | 68 (98.6) |   |
| Tumor size |   |   |   |   | 0,423 |
| Median (1st and 3rd quartile) | 13.00 (8.50; 17.00) | 11.50 (9.00; 17.75) | 10.00 (7.00; 16.00) | 14.00 (11.00; 18.00) |   |
| FNCLCC grade |   |   |   |   | 0,726 |
| I/II | 40 (24.0) | 3 (7.9) | 31 (51.7) | 6 (8.7) |   |
| III | 127 (76.0) | 35 (92.1) | 29 (48.3) | 63 (91.3) |   |
| Recist |   |   |   |   | 0,303 |
| Partial response | 44 (27.5) | 9 (29.0) | 16 (26.7) | 19 (27.5) |   |
| Stable disease | 95 (59.4) | 16 (51.6) | 33 (55.0) | 46 (66.7) |   |
| Progression disease | 21 (13.1) | 6 (19.4) | 11 (18.3) | 4 (5.8) |   |
| Radiotherapy dose |   |   |   |   | --- |
| Median (1st and 3rd quartile) | 50.00 (50.00; 50.00) | --- | 50.00 (50.00; 50.00) | 50.00 (50.00; 50.00) |   |
| Residual viable tumor  |   |   |   |   | 0,595 |
| Median (1st and 3rd quartile) | 10.00 (5.00; 40.00) | 40.00 (2.75; 70.00) | 10.00 (5.00; 40.00) | 10.00 (5.00; 20.00) |   |
| Residual viable tumor  |   |   |   |   | 0,330 |
| 0% | 18 (10.8) | 8 (21.1) | 3 (5.0) | 7 (10.1) |   |
| >0% | 149 (89.2) | 30 (78.9) | 57 (95.0) | 62 (89.9) |   |
| Residual viable tumor  |   |   |   |   | 0,293 |
| > 5% | 105 (62.9) | 27 (71.1) | 43 (71.7) | 35 (50.7) |   |
| ≤ 5% | 62 (37.1) | 11 (28.9) | 17 (28.3) | 34 (49.3) |   |
| Surgical margin |   |   |   |   | 0,211 |
| R0 | 152 (91.0) | 33 (86.8) | 53 (88.3) | 66 (95.7) |   |
| R1 | 15 (9.0) | 5 (13.2) | 7 (11.7) | 3 (4.3) |   |
| Recurrence |   |   |   |   | 0,662 |
| Local relapse | 5 (8.6) | 3 (23.1) | 1 (5.9) | 1 (3.6) |   |
| Distant metastasis | 50 (86.2) | 8 (61.5) | 15 (88.2) | 27 (96.4) |   |
| Local relapse and distant metastasis | 3 (5.2) | 2 (15.4) | 1 (5.9) | 0 (0.0) |   |